SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Balloon and missed bow spears arround . Target audience and marketing concept . This is a 3d render illustration .
Pain
AlgoTx Stumbles in Non-Opioid Pain Trial Following Vertex’s Journavx Approval
AlgoTherapeutix blames a “strong placebo effect” for the mid-stage failure for its pain gel ATX01, but the company still believes in the promise of its candidate as Vertex Pharmaceuticals’ first-in-class drug Journavx opens up the non-opioid space.
February 18, 2025
 · 
3 min read
 · 
Tristan Manalac
Podcast
A Conversation With Dannielle Appelhans, CEO of COUR
In the first podcast in a special series focused on BioSpace’s NextGen Class of 2025, Senior Editor Annalee Armstrong speaks with Dannielle Appelhans, CEO of COUR.
February 18, 2025
 · 
1 min read
 · 
Annalee Armstrong
2D illustration of kidneys
Cancer
Arcus Challenges Merck in Kidney Cancer with Early Data
Casdatifan’s progression-free survival benefits could help differentiate it from Merck’s Welireg in the kidney cancer arena, according to analysts at Truist Securities.
February 18, 2025
 · 
2 min read
 · 
Tristan Manalac
Success Way and freedom. Business woman walking to the exit through an open door.
NextGen
After 10 Years of Hard Work, COUR Treads Into Pharma’s Myasthenia Gravis Territory
COUR Pharmaceuticals has been around a while, but not until last year did the company solidify behind its ultimate mission with a series A raise.
February 18, 2025
 · 
2 min read
 · 
Annalee Armstrong
Pictured: White House/
FDA
‘No Job Security’ at FDA as Trump Team Seeks to Dismantle Workforce: Updated
The hammer came down on an unspecified number of FDA employees this weekend, days after Robert F. Kennedy Jr. was confirmed as HHS Secretary.
February 17, 2025
 · 
6 min read
 · 
Heather McKenzie
Close-Up Of Syringe With Bottles Against Blue Background
Vaccines
FDA Issues Back-to-Back Vaccine Approvals as RFK Jr. Takes HHS Seat
The approvals come as Robert F. Kennedy Jr.—who has been critical of vaccines—takes leadership of the Department of Health and Human Services.
February 17, 2025
 · 
2 min read
 · 
Tristan Manalac
Employee competency assessment. Collage of hands holding king and a pawn. Succession planning.
Cancer
Ono’s FDA Rare Cancer Approval Sets Up Face Off With Daiichi Sankyo
Ono picked up Romvimza—previously known by its active ingredient vimseltinib—from its $2.4 billion acquisition of Deciphera Pharmaceuticals in April 2024.
February 17, 2025
 · 
2 min read
 · 
Tristan Manalac
Pictured: Blue Sanofi sign on building in Germany at night
Approvals
Sanofi Challenges Novo With First FDA Nod for NovoLog Biosimilar
Merilog’s approval comes as the insulin space has over the past year suffered several setbacks, including strong calls for price caps and, potentially, the rise of the mammoth GLP-1 market.
February 17, 2025
 · 
2 min read
 · 
Tristan Manalac
Drug Development
Healthcare at a Crossroads: Maintaining Good Science in Uncertain Times
Continuing our SCOPE 2025 coverage, Rohit Nambisan, CEO at Lokavant addresses not only current challenges, but the life sciences industry’s responsibility to maintain scientific integrity.
February 17, 2025
 · 
1 min read
 · 
Lori Ellis
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS